Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1667

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7
Chunk 1667
---
 no change in our internal control over financial reporting that occurred during the year ended December 31,
2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information.

None.

Item 9C. Disclosure Regarding
Foreign Jurisdictions that Prevent Inspections.

Not applicable.

60

PART
III

Item 10. Directors, Executive
Officers, and Corporate Governance.

The following table sets forth the name, age
and position of each of our executive officers, directors and director nominees as of March 27, 2025.

    Name
     
    Age

    Position
     
    Director Since
  
    Geoffrey Dow
     
    51

    Chief Executive Officer, President and Director
     
    June 1, 2022
  
    Tyrone Miller
     
    50

    Chief Financial Officer

    Kristen Landon
     
    58

    Chief Commercial Officer

    Charles Allen
     
    49

    Director
     
    July 11, 2023
  
    Cheryl Xu
     
    57

    Director
     
    July 11, 2023
  
    Stephen Toovey
     
    71

    Director
     
    July 11, 2023
  
    Paul Field
     
    62

    Director
     
    July 11, 2023

Executive Officers and Directors

Geoffrey Dow is our Chief Executive
Officer, President, and is also one of our directors. Dr. Dow has over 20 years of product development experience in tropical diseases
and has an extensive publication and patent history. His decades of hands-on experience include 13 years in key leadership and advisory
roles in the antimalarial drug development program at the Walter Reed Army Institute of Research and at the U.S. Army Medical Materiel
Development Activity. Dr. Dow co-founded 60P in 2010. Since then, he has been involved in various projects, including leading the project
development team in securing FDA-regulatory approval for Tafenoquine (as Arakoda) for malaria prophylaxis, securing a supply chain and
access relating to Arakoda, managing post-marketing regulatory commitments, ensuring the successful prosecution of supporting patents
on which Dr. Dow was an inventor, and ensuring the company adheres to GMP, quality, and pharmacovigilance requirements. Dr